Nautilus Biotechnology (NAUT) Net Income (2020 - 2021)

Nautilus Biotechnology (NAUT) reported Net Income of -$2.1 million for Q1 2021, down 51.16% sequentially from -$1.4 million in Q4 2020.

Nautilus Biotechnology (NAUT) Net Income (2020 - 2021) Analysis & Trends

Nautilus Biotechnology (NAUT) has 2 years of Net Income data on file, last reported at -$2.1 million in Q1 2021.

For the quarter ending Q1 2021, Net Income changed N/A year-over-year to -$2.1 million; the trailing twelve-month figure through Dec 2021 stood at -$2.1 million (changed N/A YoY), and the FY2020 full-year result was -$41.3 million, changed N/A from the prior year.
Net Income slipped to -$2.1 million in Q1 2021, from -$1.4 million in the prior quarter.
In the past five years, Net Income ranged from a high of -$586388.0 in Q3 2020 to a low of -$2.1 million in Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Income (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-37.09 Mn
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	227.36 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-3.31 Mn
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	1.03 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	727.20 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-26.94 Mn
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	362.00 Mn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-453.82 Mn
10	Nautilus Biotechnology	224.14 Mn	224.14 Mn	-	-

Download Data